Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.
Level 5 - mechanism / opinion, no new human data
Narrative review of structural mechanisms and preclinical data without systematic review methodology or primary human data.
PubMed 27277824 · doi:10.1007/s00109-016-1427-y
What was done
This is a narrative review describing the structural biology of apolipoprotein E isoforms (apoE2, apoE3, apoE4) and summarizing mechanistic evidence linking them to cardiovascular disease and neurodegenerative disorders such as Alzheimer's disease.
What was found
The abstract reports mechanistic pathways rather than quantitative clinical trial results. ApoE2 and apoE4 increase cardiovascular risk by altering lipoprotein binding and LDL receptor dynamics. In neurons, apoE4 exhibits an abnormal domain interaction between its carboxyl- and amino-terminals, resulting in neuron-specific proteolysis into 12-29 kDa neurotoxic fragments that induce mitochondrial dysfunction and cytoskeletal alterations, including tau phosphorylation. Small-molecule structure correctors can prevent this domain interaction, converting apoE4 to structurally and functionally mimic apoE3.
Why it matters
The paper outlines how a single amino acid difference alters apoE conformation to drive dual vascular and neurodegenerative pathologies, pointing to structural correctors as potential therapeutics.
Limits
As a narrative review, the abstract provides no primary human data, quantitative effect estimates, search criteria, or clinical trial outcomes. Proposed therapeutic interventions remain at the preclinical stage.
Cited by
- context Apolipoprotein E was discovered by Robert Mahley.